RecruitingNot ApplicableNCT06906627

Implementation pRogram to Improve Screening and Management for CKD in Diabetes (Program 1) (IRIS-CKD)

Implementation pRogram to Improve Screening and Management for CKD in Diabetes (IRIS-CKD)

Sponsor

Duke University

Enrollment

750 participants

Start Date

Oct 28, 2025

Study Type

INTERVENTIONAL

Conditions

Type 2 Diabetes Mellitus (T2DM)Chronic Kidney Disease(CKD)Type 2 DM

Summary

IRIS-CKD is an implementation study to improve guideline-recommended screening of chronic kidney disease (CKD) in individuals with type 2 diabetes (T2D) in the United States.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study (Program 1 of IRIS-CKD) is testing a healthcare system-level program to improve screening for chronic kidney disease (CKD) in adults with type 2 diabetes who have not had a kidney function or urine test in the past 15 months — helping to catch kidney disease earlier. **You may be eligible if...** - You are an adult with type 2 diabetes - You receive primary care within the participating healthcare system and have had a visit with your primary care provider in the past 24 months - You have not had an eGFR (kidney filtration) test or urine albumin test within the past 15 months **You may NOT be eligible if...** - You have already been diagnosed with chronic kidney disease (CKD) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHER(IRIS-CKD Screening Program): Home Kit

All participants approached for enrollment in Program 1 will receive National Kidney Foundational educational materials related to CKD screening in type 2 diabetes and study information. All enrolled participants will receive a message regarding study lab(s) results. Home Test Kit: a kit delivered to participants homes with instructions to complete eGFR (fingerstick) and/or UACR (urine sample) testing, depending on which lab(s) are missing at baseline.

OTHER(IRIS-CKD Screening Program): Standard Lab Order

ll participants approached for enrollment in Program 1 will receive National Kidney Foundation educational materials related to CKD screening in type 2 diabetes and study information. All enrolled participants will receive a message regarding study lab

Locations(6)

University of Alabama

Birmingham, Alabama, United States

Orlando Health

St. Petersburg, Florida, United States

University of Michigan

Ann Arbor, Michigan, United States

Essentia Health

Duluth, Minnesota, United States

Duke University

Durham, North Carolina, United States

Baylor Scott & White

Temple, Texas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06906627

Related Trials

Effect of Early Combination Antihyperglycemic Treatment on Metabolic Control in Individuals With Type 2 Diabetes

NCT066138541 location

Optimization and Evaluation of the Diagnosis and Treatment System for Diabetic Retinopathy in Type 2 Diabetes Mellitus

NCT068213993 locations

A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus

NCT074652241 location

A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM

NCT0684520220 locations

Glycemic Control With Triple Pathway Approach Through Empagliflozin, Linagliptin and Metformin Combination

NCT068627392 locations